European Heart Journal最新文献

筛选
英文 中文
Correction to: Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study. 更正:心梗后早期左心室功能障碍中室性心律失常的预后价值:法国全国性 WICD-MI 研究。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-10-01 DOI: 10.1093/eurheartj/ehae693
{"title":"Correction to: Prognostic value of ventricular arrhythmia in early post-infarction left ventricular dysfunction: the French nationwide WICD-MI study.","authors":"","doi":"10.1093/eurheartj/ehae693","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae693","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mucolipidosis III: a rare phenocopy of inherited metabolic cardiomyopathy. 粘脂病 III:遗传性代谢性心肌病的罕见表型。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-09-30 DOI: 10.1093/eurheartj/ehae636
Xia Gu, Linlin Dai, Minjie Lu
{"title":"Mucolipidosis III: a rare phenocopy of inherited metabolic cardiomyopathy.","authors":"Xia Gu, Linlin Dai, Minjie Lu","doi":"10.1093/eurheartj/ehae636","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae636","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study 2019年成人冠状病毒疾病疫苗接种后的心血管事件:一项全国性瑞典研究
IF 39.3 1区 医学
European Heart Journal Pub Date : 2024-09-30 DOI: 10.1093/eurheartj/ehae639
Yiyi Xu, Huiqi Li, Ailiana Santosa, Björn Wettermark, Tove Fall, Jonas Björk, Mats Börjesson, Magnus Gisslén, Fredrik Nyberg
{"title":"Cardiovascular events following coronavirus disease 2019 vaccination in adults: a nationwide Swedish study","authors":"Yiyi Xu, Huiqi Li, Ailiana Santosa, Björn Wettermark, Tove Fall, Jonas Björk, Mats Börjesson, Magnus Gisslén, Fredrik Nyberg","doi":"10.1093/eurheartj/ehae639","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae639","url":null,"abstract":"Background and Aims While the rationale for coronavirus disease 2019 (COVID-19) vaccination is to reduce complications and overall mortality, some cardiovascular complications from the vaccine itself have been demonstrated. Myocarditis and pericarditis are recognized as rare acute adverse events after mRNA vaccines in young males, while evidence regarding other cardiovascular events remains limited and inconsistent. This study assessed the risks of several cardiovascular and cerebrovascular events in a Swedish nationwide register-based cohort. Methods Post-vaccination risk of myocarditis/pericarditis, dysrhythmias, heart failure, myocardial infarction, and cerebrovascular events (transient ischaemic attack and stroke) in several risk windows after each vaccine dose were assessed among all Swedish adults (n = 8 070 674). Hazard ratios (HRs) with 95% confidence intervals (95% CIs) compared with unvaccinated were estimated from Cox regression models adjusted for potential confounders. Results For most studied outcomes, decreased risks of cardiovascular events post-vaccination were observed, especially after dose three (HRs for dose three ranging from .69 to .81), while replicating the increased risk of myocarditis and pericarditis 1–2 weeks after COVID-19 mRNA vaccination. Slightly increased risks, similar across vaccines, were observed for extrasystoles [HR 1.17 (95% CI 1.06–1.28) for dose one and HR 1.22 (95% CI 1.10–1.36) for dose two, stronger in elderly and males] but not for arrhythmias and for transient ischaemic attack [HR 1.13 (95% CI 1.05–1.23), mainly in elderly] but not for stroke. Conclusions Risk of myopericarditis (mRNA vaccines only), extrasystoles, and transient ischaemic attack was transiently increased after COVID-19 vaccination, but full vaccination substantially reduced the risk of several more severe COVID-19-associated cardiovascular outcomes, underscoring the protective benefits of complete vaccination.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":39.3,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142330100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fusion mixed reality: a novel approach to merge the physical and virtual cath lab. 融合混合现实:融合物理和虚拟阴道实验室的新方法。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-09-30 DOI: 10.1093/eurheartj/ehae632
João Silva Marques, Catarina Oliveira, Fausto J Pinto
{"title":"Fusion mixed reality: a novel approach to merge the physical and virtual cath lab.","authors":"João Silva Marques, Catarina Oliveira, Fausto J Pinto","doi":"10.1093/eurheartj/ehae632","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae632","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Guidelines and a focus on ischaemic heart disease, atrial fibrillation, innovative treatments of channelopathies. 新指南,重点关注缺血性心脏病、心房颤动、通道病的创新治疗。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-09-29 DOI: 10.1093/eurheartj/ehae638
Filippo Crea
{"title":"New Guidelines and a focus on ischaemic heart disease, atrial fibrillation, innovative treatments of channelopathies.","authors":"Filippo Crea","doi":"10.1093/eurheartj/ehae638","DOIUrl":"https://doi.org/10.1093/eurheartj/ehae638","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome. 1 型长 QT 综合征转基因兔的 KCNQ1 抑制替代基因疗法。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-09-29 DOI: 10.1093/eurheartj/ehae476
Sahej Bains, Lucilla Giammarino, Saranda Nimani, Nicolo Alerni, David J Tester, C S John Kim, Nicolas Christoforou, Julien Louradour, András Horváth, Olgica Beslac, Miriam Barbieri, Lluis Matas, Thomas S Hof, Ruben Lopez, Stefanie Perez-Feliz, Chiara Parodi, Luisana G Garcia Casalta, Jacqulyn Jurgensen, Michael A Barry, Mariana Bego, Lisa Keyes, Jane Owens, Jason Pinkstaff, Gideon Koren, Manfred Zehender, Michael Brunner, Daniela Casoni, Fabien Praz, Andreas Haeberlin, Gabriel Brooks, Michael J Ackerman, Katja E Odening
{"title":"KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome.","authors":"Sahej Bains, Lucilla Giammarino, Saranda Nimani, Nicolo Alerni, David J Tester, C S John Kim, Nicolas Christoforou, Julien Louradour, András Horváth, Olgica Beslac, Miriam Barbieri, Lluis Matas, Thomas S Hof, Ruben Lopez, Stefanie Perez-Feliz, Chiara Parodi, Luisana G Garcia Casalta, Jacqulyn Jurgensen, Michael A Barry, Mariana Bego, Lisa Keyes, Jane Owens, Jason Pinkstaff, Gideon Koren, Manfred Zehender, Michael Brunner, Daniela Casoni, Fabien Praz, Andreas Haeberlin, Gabriel Brooks, Michael J Ackerman, Katja E Odening","doi":"10.1093/eurheartj/ehae476","DOIUrl":"10.1093/eurheartj/ehae476","url":null,"abstract":"<p><strong>Background and aims: </strong>Type 1 long QT syndrome (LQT1) is caused by pathogenic variants in the KCNQ1-encoded Kv7.1 potassium channels, which pathologically prolong ventricular action potential duration (APD). Herein, the pathologic phenotype in transgenic LQT1 rabbits is rescued using a novel KCNQ1 suppression-replacement (SupRep) gene therapy.</p><p><strong>Methods: </strong>KCNQ1-SupRep gene therapy was developed by combining into a single construct a KCNQ1 shRNA (suppression) and an shRNA-immune KCNQ1 cDNA (replacement), packaged into adeno-associated virus serotype 9, and delivered in vivo via an intra-aortic root injection (1E10 vg/kg). To ascertain the efficacy of SupRep, 12-lead electrocardiograms were assessed in adult LQT1 and wild-type (WT) rabbits and patch-clamp experiments were performed on isolated ventricular cardiomyocytes.</p><p><strong>Results: </strong>KCNQ1-SupRep treatment of LQT1 rabbits resulted in significant shortening of the pathologically prolonged QT index (QTi) towards WT levels. Ventricular cardiomyocytes isolated from treated LQT1 rabbits demonstrated pronounced shortening of APD compared to LQT1 controls, leading to levels similar to WT (LQT1-UT vs. LQT1-SupRep, P < .0001, LQT1-SupRep vs. WT, P = ns). Under β-adrenergic stimulation with isoproterenol, SupRep-treated rabbits demonstrated a WT-like physiological QTi and APD90 behaviour.</p><p><strong>Conclusions: </strong>This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with LQT1.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial. 更正:静脉注射铁剂治疗心力衰竭、缺铁定义和临床反应:IRONMAN 试验。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-09-29 DOI: 10.1093/eurheartj/ehae243
{"title":"Correction to: Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial.","authors":"","doi":"10.1093/eurheartj/ehae243","DOIUrl":"10.1093/eurheartj/ehae243","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142008489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial. 动脉粥样硬化量化与心血管风险:ISCHEMIA 试验。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-09-29 DOI: 10.1093/eurheartj/ehae471
Nick S Nurmohamed, James K Min, Rebecca Anthopolos, Harmony R Reynolds, James P Earls, Tami Crabtree, G B John Mancini, Jonathon Leipsic, Matthew J Budoff, Cameron J Hague, Sean M O'Brien, Gregg W Stone, Jeffrey S Berger, Robert Donnino, Mandeep S Sidhu, Jonathan D Newman, William E Boden, Bernard R Chaitman, Peter H Stone, Sripal Bangalore, John A Spertus, Daniel B Mark, Leslee J Shaw, Judith S Hochman, David J Maron
{"title":"Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.","authors":"Nick S Nurmohamed, James K Min, Rebecca Anthopolos, Harmony R Reynolds, James P Earls, Tami Crabtree, G B John Mancini, Jonathon Leipsic, Matthew J Budoff, Cameron J Hague, Sean M O'Brien, Gregg W Stone, Jeffrey S Berger, Robert Donnino, Mandeep S Sidhu, Jonathan D Newman, William E Boden, Bernard R Chaitman, Peter H Stone, Sripal Bangalore, John A Spertus, Daniel B Mark, Leslee J Shaw, Judith S Hochman, David J Maron","doi":"10.1093/eurheartj/ehae471","DOIUrl":"10.1093/eurheartj/ehae471","url":null,"abstract":"<p><strong>Background and aims: </strong>The aim of this study was to determine the prognostic value of coronary computed tomography angiography (CCTA)-derived atherosclerotic plaque analysis in ISCHEMIA.</p><p><strong>Methods: </strong>Atherosclerosis imaging quantitative computed tomography (AI-QCT) was performed on all available baseline CCTAs to quantify plaque volume, composition, and distribution. Multivariable Cox regression was used to examine the association between baseline risk factors (age, sex, smoking, diabetes, hypertension, ejection fraction, prior coronary disease, estimated glomerular filtration rate, and statin use), number of diseased vessels, atherosclerotic plaque characteristics determined by AI-QCT, and a composite primary outcome of cardiovascular death or myocardial infarction over a median follow-up of 3.3 (interquartile range 2.2-4.4) years. The predictive value of plaque quantification over risk factors was compared in an area under the curve (AUC) analysis.</p><p><strong>Results: </strong>Analysable CCTA data were available from 3711 participants (mean age 64 years, 21% female, 79% multivessel coronary artery disease). Amongst the AI-QCT variables, total plaque volume was most strongly associated with the primary outcome (adjusted hazard ratio 1.56, 95% confidence interval 1.25-1.97 per interquartile range increase [559 mm3]; P = .001). The addition of AI-QCT plaque quantification and characterization to baseline risk factors improved the model's predictive value for the primary outcome at 6 months (AUC 0.688 vs. 0.637; P = .006), at 2 years (AUC 0.660 vs. 0.617; P = .003), and at 4 years of follow-up (AUC 0.654 vs. 0.608; P = .002). The findings were similar for the other reported outcomes.</p><p><strong>Conclusions: </strong>In ISCHEMIA, total plaque volume was associated with cardiovascular death or myocardial infarction. In this highly diseased, high-risk population, enhanced assessment of atherosclerotic burden using AI-QCT-derived measures of plaque volume and composition modestly improved event prediction.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11439108/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution. 出血风险应指导经皮冠状动脉介入治疗后的抗血栓治疗:哥白尼式的革命。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-09-29 DOI: 10.1093/eurheartj/ehae542
Marco Valgimigli, Antonio Landi
{"title":"Bleeding risk should guide antithrombotic treatment after percutaneous coronary intervention: a Copernican revolution.","authors":"Marco Valgimigli, Antonio Landi","doi":"10.1093/eurheartj/ehae542","DOIUrl":"10.1093/eurheartj/ehae542","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From a club of friends to an institution: past successes and future challenges for the European Society of Cardiology. 从朋友俱乐部到机构:欧洲心脏病学会过去的成功和未来的挑战。
IF 37.6 1区 医学
European Heart Journal Pub Date : 2024-09-29 DOI: 10.1093/eurheartj/ehae505
Thomas F Lüscher
{"title":"From a club of friends to an institution: past successes and future challenges for the European Society of Cardiology.","authors":"Thomas F Lüscher","doi":"10.1093/eurheartj/ehae505","DOIUrl":"10.1093/eurheartj/ehae505","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":null,"pages":null},"PeriodicalIF":37.6,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信